Medindia

X

Sales of Drugs From Multinational Corporations Will Represent 92 Percent of Mexico's Non-Small-Cell Lung Cancer Drug Market in 2014

Thursday, July 29, 2010 Drug News J E 4
Advertisement
Merck KGaA's Erbitux and Bayer's Nexavar Are Expected to Be Approved for Non-Small-Cell Lung Cancer in Mexico During the 2009 - 2014 Study Period, According to a New Report from Decision Resources

For more information, contact:

Christopher Comfort

Decision Resources

781-296-2597

ccomfort@dresources.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Intra-Cellular Therapies Announces the Successful ...
S
Deloitte Becomes a HITRUST Common Security Framewo...